Zobrazeno 1 - 10
of 168
pro vyhledávání: '"William A, Wegener"'
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
Purpose: Sacituzumab govitecan (IMMU-132) is an antibody–drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. This phase I trial evaluated thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b1720f9bb447ea9eda94114d5c9e67d
https://doi.org/10.1158/1078-0432.c.6523517
https://doi.org/10.1158/1078-0432.c.6523517
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients.Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1–7) mSCLC who rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85d3221b48c4ae9f44d5518d04b2e195
https://doi.org/10.1158/1078-0432.c.6526244.v1
https://doi.org/10.1158/1078-0432.c.6526244.v1
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
Serum concentration of intact sacituzumab govitecan and hRS7 IgG taken 30 min after injection for each of the 4 dose levels tested.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2455a3d85f2cadfc9c90464a485cb5fc
https://doi.org/10.1158/1078-0432.22457147
https://doi.org/10.1158/1078-0432.22457147
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
This file contains additional methods, including eligibility criteria, study design, pharmacokinetics and immunogenicity, and immunohistology, as well as additional results related to several notable patient narratives.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c35566f1635eeaa794737d1de0e61a4
https://doi.org/10.1158/1078-0432.22457150
https://doi.org/10.1158/1078-0432.22457150
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Immunohistology expression of Trop-2 vs response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39c28d7d0d017206cdcb8eeb9b98c5f6
https://doi.org/10.1158/1078-0432.22466114
https://doi.org/10.1158/1078-0432.22466114
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
Time to progression in relation to the immunohistological score in 16 patients with diverse cancers enrolled in the sacituzumab govitecan trial who provided archival tissue specimens.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b466689fca03af0b9a50a231e8f610f
https://doi.org/10.1158/1078-0432.22457153.v1
https://doi.org/10.1158/1078-0432.22457153.v1
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
Trop-2 expression in archived tissue specimens from 6 patients enrolled in the clinical trial with sacituzumab govitecan.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0a91efb968a0bf05043b6d26295d33c
https://doi.org/10.1158/1078-0432.22457156
https://doi.org/10.1158/1078-0432.22457156
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Evaluation of IHC staining vs best overall response in SCLC treated with 8 or 10 mg/kg starting dose of sacituzumab govitecan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b47b04cd98cbbe62d66c192352ea6bce
https://doi.org/10.1158/1078-0432.22466111
https://doi.org/10.1158/1078-0432.22466111
Autor:
Patrice Chevallier, Sylvain Chantepie, Francoise Huguet, Emmanuel Raffoux, Xavier Thomas, Thibaut Leguay, Tony Marchand, Francoise Isnard, Aude Charbonnier, Sébastien Maury, Maria-Pilar Gallego-Hernanz, Nelly Robillard, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Fanny Rialland, Claire Le Houerou, David M. Goldenberg, William A. Wegener, Marie-C. Béné, Hervé Dombret
Publikováno v:
Haematologica, Vol 102, Iss 5 (2017)
Externí odkaz:
https://doaj.org/article/090e5a27205645728dd86e8f56925ba9
Autor:
Howard A. Liebman, Mansoor N. Saleh, James B. Bussel, O. George Negrea, Heather Horne, William A. Wegener, David M. Goldenberg
Publikováno v:
Haematologica, Vol 101, Iss 11 (2016)
We compared two dosing schedules for subcutaneous injections of a low-dose humanized anti-CD20 antibody, veltuzumab, in immune thrombocytopenia. Fifty adults with primary immune thrombocytopenia, in whom one or more lines of standard therapy had fail
Externí odkaz:
https://doaj.org/article/3468c03b2c6244a99abe705700aaa8c4